



Precision BioSciences to Present at Upcoming Virtual Investor Conferences

March 2, 2021

DURHAM, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and *in vivo* gene correction therapies with its ARCUS[®] genome editing platform, today announced management will participate in the following upcoming virtual investor conferences:

H.C. Wainwright Global Life Sciences Conference

Date: Tuesday, March 9, 2021

The fireside chat will be available on demand beginning at 7:00 AM ET with an archived replay available for 90 days.

Barclays Global Healthcare Conference

Date: Tuesday, March 9, 2021

Presentation: 10:55 AM ET

An archived replay of this corporate presentation will be available for one year.

Webcasts will be accessible on the Company's website, www.precisionbiosciences.com, in the Investors & Media section under Events and Presentations.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS[®] genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple "off-the-shelf" CAR T immunotherapy clinical candidates and several *in vivo* gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

Investor Contact:

Alex Kelly

Interim Chief Financial Officer

Alex.Kelly@precisionbiosciences.com

Media Contact:

Maurissa Messier

Senior Director, Corporate Communications

Maurissa.Messier@precisionbiosciences.com